![Atul Saran](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Atul Saran
Keine laufenden Positionen mehr
Profil
Atul Saran is Chief Executive Officer & Director at IntegerBio, Inc. since 2023.
Director at Emergent Product Development UK Ltd. since 2017.
Secretary & Director at Emergent Countermeasures International Ltd. since 2018.
Member of The District of Columbia Bar.
Formerly Director at Inotek Pharmaceuticals Corp., Arriva Pharmaceuticals, Inc., and VentiRx Pharmaceuticals, Inc. Independent Director at Xencor, Inc. from 2011 to 2014.
Vice President-Corporate Development & Ventures at MedImmune LLC from 2003 to 2014.
Vice President-Corporate Development & Ventures at AstraZeneca PLC from 2013 to 2014.
SVP-Corporate Development & Ventures at MedImmune Ventures, Inc. Senior Vice President & General Counsel at MacroGenics, Inc. from 2014 to 2017.
Associate Attorney at Hogan & Hartson LLP.
Executive VP, Chief Strategy & Development Officer at Emergent BioSolutions, Inc. from 2022 to 2023.
Member of California State Bar Association.
Education includes undergraduate degree from Stanford University, MBA from MIT Sloan School of Management, and graduate degree from the University of Illinois College of Law.
Aktive Positionen von Atul Saran
| Unternehmen | Position | Beginn |
|---|---|---|
The District of Columbia Bar
 The District of Columbia Bar Miscellaneous Commercial ServicesCommercial Services Provides legal services | Corporate Officer/Principal | - |
Emergent Product Development UK Ltd.
 Emergent Product Development UK Ltd. Pharmaceuticals: MajorHealth Technology Develops oral vaccines for typhoid, travelers diarrhea, hepatitis B and anthrax | Direktor/Vorstandsmitglied | 20.12.2017 |
Emergent Countermeasures International Ltd.
 Emergent Countermeasures International Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical preparations | Direktor/Vorstandsmitglied | 18.12.2018 |
Ehemalige bekannte Positionen von Atul Saran
| Unternehmen | Position | Ende |
|---|---|---|
| EMERGENT BIOSOLUTIONS INC. | General Counsel | 01.03.2022 |
| MACROGENICS, INC. | General Counsel | 01.05.2017 |
California State Bar Association | Corporate Officer/Principal | 15.05.2014 |
| XENCOR, INC. | Direktor/Vorstandsmitglied | 23.01.2014 |
| ASTRAZENECA PLC | Corporate Officer/Principal | 01.01.2014 |
Ausbildung von Atul Saran
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
77
Beziehungen ersten Grades
17
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 17 |
|---|---|
MedImmune LLC
 MedImmune LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Inotek Pharmaceuticals Corp.
 Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Engages in the development, discovery and commercialization of therapies for glaucoma and other diseases of the eye | Health Technology |
Arriva Pharmaceuticals, Inc.
 Arriva Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops anti-inflammatory therapies for treating respiratory diseases | Health Technology |
MedImmune Ventures, Inc.
 MedImmune Ventures, Inc. Investment ManagersFinance MedImmune Ventures invests in private biotechnology companies located across the globe primarily in North America. The firm focuses on healthcare sectors such as molecules, vaccines, pharmaceutical technologies, medical devices, diagnostics, imaging and healthcare IT. The firm provides financing for seed, early, later and mezzanine stage capital requirements with an investment size ranging from USD 5 - USD 10 million per round. It acts as a lead investor and takes an active role on the board of directors. | Finance |
Xencor, Inc.
 Xencor, Inc. BiotechnologyHealth Technology Develops therapeutics to treat autoimmune and allergic diseases, cancer and other conditions | Health Technology |
VentiRx Pharmaceuticals, Inc.
 VentiRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel medicines | Health Technology |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
MacroGenics, Inc.
 MacroGenics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes antibody-based therapeutics for the treatment of cancer | Health Technology |
Hogan & Hartson LLP
 Hogan & Hartson LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
Emergent BioSolutions, Inc.
 Emergent BioSolutions, Inc. Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products | Health Technology |
Emergent Product Development UK Ltd.
Emergent Product Development UK Ltd. Pharmaceuticals: MajorHealth Technology Develops oral vaccines for typhoid, travelers diarrhea, hepatitis B and anthrax | Health Technology |
The District of Columbia Bar
The District of Columbia Bar Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
California State Bar Association | |
MIT Sloan School of Management
 MIT Sloan School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Illinois College of Law
 University of Illinois College of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Emergent Countermeasures International Ltd.
Emergent Countermeasures International Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical preparations | Health Technology |
